GS
PCRX icon

Gagnon Securities’s Pacira BioSciences PCRX Stock Holding History

Gagnon Securities’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.4M Sell
608,617
-8,893
-1% -$210K 2.98% 12
2026
Q1 		$14M Buy
617,510
+116,299
+23% +$2.58M 3.22% 10
2025
Q4 		$13M Buy
501,211
+51,494
+11% +$1.22M 2.64% 14
2025
Q3 		$11.6M Buy
449,717
+81,364
+22% +$2M 2.32% 17
2025
Q2 		$8.8M Buy
368,353
+60,019
+19% +$1.51M 1.79% 24
2025
Q1 		$7.66M Sell
308,334
-13,409
-4% -$321K 1.69% 23
2024
Q4 		$6.06M Buy
321,743
+14,800
+5% +$260K 1.22% 26
2024
Q3 		$4.62M Sell
306,943
-289,648
-49% -$4.95M 0.92% 33
2024
Q2 		$17.1M Buy
596,591
+47,623
+9% +$1.36M 3.84% 5
2024
Q1 		$16M Buy
548,968
+3,389
+0.6% +$104K 3.8% 5
2023
Q4 		$18.4M Sell
545,579
-19,850
-4% -$581K 4.42% 5
2023
Q3 		$17.3M Buy
565,429
+6,220
+1% +$224K 4.35% 5
2023
Q2 		$22.4M Sell
559,209
-2,501
-0.4% -$103K 4.66% 4
2023
Q1 		$22.9M Sell
561,710
-1,705
-0.3% -$67.8K 4.82% 4
2022
Q4 		$21.8M Sell
563,415
-11,193
-2% -$545K 4.8% 3
2022
Q3 		$30.6M Sell
574,608
-19,784
-3% -$1.1M 6.72% 1
2022
Q2 		$34.7M Sell
594,392
-16,541
-3% -$1.08M 7.26% 1
2022
Q1 		$46.6M Sell
610,933
-2,857
-0.5% -$190K 7.6% 1
2021
Q4 		$36.9M Buy
613,790
+43,147
+8% +$2.38M 5.54% 4
2021
Q3 		$32M Buy
570,643
+71,310
+14% +$4.11M 4.75% 3
2021
Q2 		$30.3M Buy
499,333
+44,484
+10% +$2.82M 4.3% 5
2021
Q1 		$31.9M Buy
454,849
+19,894
+5% +$1.42M 4.85% 4
2020
Q4 		$26M Buy
434,955
+9,288
+2% +$544K 4.14% 6
2020
Q3 		$25.6M Buy
425,667
+3,526
+0.8% +$205K 5.46% 3
2020
Q2 		$22.1M Buy
422,141
+14,982
+4% +$626K 5.36% 3
2020
Q1 		$13.7M Buy
407,159
+21,247
+6% +$883K 4.64% 5
2019
Q4 		$17.5M Sell
385,912
-1,467
-0.4% -$62.3K 3.83% 7
2019
Q3 		$14.7M Buy
387,379
+108,766
+39% +$4.34M 3.49% 8
2019
Q2 		$12.1M Buy
+278,613
New +$11.8M 2.61% 14

Other funds holding PCRX

GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BS
Banco Santander Madrid, Spain $16.1B AUM 35.02% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Gagnon Securities's PCRX Position: Q2 2026 in Review

Gagnon Securities reduced its Pacira BioSciences (PCRX) stake by 1.4% in Q2 2026, selling an estimated $210K and leaving 608,617 shares worth $15.4M. The position accounts for 2.98% of the portfolio, ranked #12.

Gagnon Securities first reported a position in PCRX in Q2 2019 and has held it in 29 quarters since. The position peaked at $46.6M in Q1 2022. 68 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Gagnon Securities held 608,617 shares of Pacira BioSciences worth $15.4M as of Q2 2026.
  • Gagnon Securities sold 8,893 Pacira BioSciences shares in Q2 2026, an estimated $210K.
  • Pacira BioSciences made up 2.98% of Gagnon Securities's portfolio in Q2 2026, its #12 holding.
  • Gagnon Securities first reported a position in Pacira BioSciences in Q2 2019 and has held it in 29 quarters since.
  • Gagnon Securities's Pacira BioSciences position peaked at $46.6M in Q1 2022.
  • 68 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Gagnon Securities's 13F filing for Q2 2026, filed 5 Aug 2026.